Re-Evaluating Multi-Kinase Inhibitors Targeting FGFR and VEGFR Pathways for Combined Therapy in Colorectal Cancer: A Preclinical Study. (PubMed, Cancers (Basel)) - Oct 17, 2026 - "In particular, Pemigatinib and Infigratinib ranked among the top eight tested selective and non-selective FGFR/VEGFR inhibitors that effectively resensitized all types of CRCs to the DNA topoisomerase II inhibitor Doxorubicin and, in fewer experimental settings, to the antimetabolite 5-Fluorouracil...The enhancement of pro-apoptotic activity of Doxorubicin when co-treated with Pemigatinib, Lucitanib, and Regorafenib in HCT116 cells was consistent with a decrease in proliferative activity in CRCs treated with these RTKIs alone...Indeed, in HCT116 cells, Lucitanib and, to a lesser extent, Pemigatinib impaired the efflux of the intrinsically fluorescent Doxorubicin and Mitoxantrone...Consistent with these findings, immunohistochemical (IHC) staining revealed a substantial increase in apoptotic cells (e.g., cleaved caspase-3-positive) and a decrease in proliferative cells (e.g., Ki-67-positive) in allografts from animals treated with a combination of Infigratinib..."
Journal • Preclinical • Breast Cancer • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor • ABCB1 • ABCG2 • CASP3
|
|
Aigul Galembikova; Alina Galyautdinova; Emiliya S Egorova; Natalya Andriutsa; Pavel B Kopnin; Pavel Dunaev; Sergei Boichuk; Tatyana Gessel
|